^
Association details:
| Biomarker: | PIK3CA mutation |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | pictilisib (GDC-0941) (PI3K inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Phosphoinositide 3-Kinase (PI3K) Pathway Alterations Are Associated with Histologic Subtypes and Are Predictive of Sensitivity to PI3K Inhibitors in Lung Cancer Preclinical Models
Excerpt:
...the GDC-0941/MEK inhibitor combination showed the strongest combination effects, and was particularly effective in cell lines with EGFR activation, PIK3CA mutations, or KRAS mutations...
Secondary therapy:
MEK Inhibitor
DOI:
10.1158/1078-0432.CCR-12-2347
